ASX - By Stock
|
RCE |
Re:
Ann: Placement and Entitlement Offer
|
|
Alv917
|
101 |
33K |
11 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
101
|
33K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Need to push the IV dose higher
|
|
Alv917
|
26 |
9.9K |
0 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
26
|
9.9K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Conversion of Performance Shares
|
|
Alv917
|
59 |
22K |
5 |
05/09/22 |
05/09/22 |
ASX - By Stock
|
59
|
22K
|
5
|
|
ASX - By Stock
|
NC6 |
Re:
General Discussion
|
|
Alv917
|
1.3K |
334K |
4 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
1.3K
|
334K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: European Patent for AD-214 granted
|
|
Alv917
|
2 |
1.3K |
2 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
2
|
1.3K
|
2
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Alv917
|
2.1K |
625K |
4 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
2.1K
|
625K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Positive Safety Data - 4000mg Complete
|
|
Alv917
|
46 |
19K |
3 |
26/06/22 |
26/06/22 |
ASX - By Stock
|
46
|
19K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Positive Safety Data - 4000mg Complete
|
|
Alv917
|
46 |
19K |
5 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
46
|
19K
|
5
|
|
ASX - By Stock
|
BCB |
Re:
Royalty
|
|
Alv917
|
73 |
28K |
8 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
73
|
28K
|
8
|
|
ASX - By Stock
|
BCB |
Re:
Royalty
|
|
Alv917
|
73 |
28K |
2 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
73
|
28K
|
2
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: NC6 Signs MOU With One of World's Largest Fashion Retailers
|
|
Alv917
|
26 |
7.6K |
6 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
26
|
7.6K
|
6
|
|
ASX - By Stock
|
NC6 |
Re:
News and media
|
|
Alv917
|
692 |
208K |
5 |
19/01/22 |
19/01/22 |
ASX - By Stock
|
692
|
208K
|
5
|
|
ASX - By Stock
|
NC6 |
Re:
News and media
|
|
Alv917
|
692 |
208K |
2 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
692
|
208K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Second Cohort of PI Clinical Trial
|
|
Alv917
|
44 |
12K |
9 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
44
|
12K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Second Cohort of PI Clinical Trial
|
|
Alv917
|
44 |
12K |
1 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
44
|
12K
|
1
|
|
ASX - By Stock
|
NC6 |
Re:
General Discussion
|
|
Alv917
|
1.3K |
334K |
2 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
1.3K
|
334K
|
2
|
|
ASX - By Stock
|
NC6 |
Re:
General Discussion
|
|
Alv917
|
1.3K |
334K |
3 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
1.3K
|
334K
|
3
|
|
ASX - By Stock
|
AKG |
Re:
Ann: Preliminary Final Report
|
|
Alv917
|
10 |
4.6K |
0 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
10
|
4.6K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Court application and delayed cleansing notice
|
|
Alv917
|
32 |
9.4K |
3 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
32
|
9.4K
|
3
|
|
ASX - By Stock
|
BCA |
Re:
Ann: Maiden Manganese Resource for LR1 Prospect at Flanagan Bore
|
|
Alv917
|
8 |
2.9K |
7 |
05/10/21 |
05/10/21 |
ASX - By Stock
|
8
|
2.9K
|
7
|
|
ASX - By Stock
|
BCC |
Re:
BCC updated valuation. +$1 by FY23 end
|
|
Alv917
|
340 |
77K |
3 |
05/09/21 |
05/09/21 |
ASX - By Stock
|
340
|
77K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Change in substantial holding
|
|
Alv917
|
77 |
23K |
1 |
22/08/21 |
22/08/21 |
ASX - By Stock
|
77
|
23K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Change in substantial holding
|
|
Alv917
|
77 |
23K |
6 |
21/08/21 |
21/08/21 |
ASX - By Stock
|
77
|
23K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Change in substantial holding
|
|
Alv917
|
77 |
23K |
1 |
21/08/21 |
21/08/21 |
ASX - By Stock
|
77
|
23K
|
1
|
|
ASX - By Stock
|
BCA Mining |
Re:
General Discussion
|
|
Alv917
|
36 |
12K |
3 |
22/07/21 |
22/07/21 |
ASX - By Stock
|
36
|
12K
|
3
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Alv917
|
2.1K |
625K |
3 |
02/07/21 |
02/07/21 |
ASX - By Stock
|
2.1K
|
625K
|
3
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Alv917
|
2.1K |
625K |
0 |
01/07/21 |
01/07/21 |
ASX - By Stock
|
2.1K
|
625K
|
0
|
|
ASX - By Stock
|
BCA |
Re:
Ann: Manganese Mineralisation Extended by 5km at Flanagan Bore
|
|
Alv917
|
6 |
2.9K |
3 |
01/07/21 |
01/07/21 |
ASX - By Stock
|
6
|
2.9K
|
3
|
|
ASX - By Stock
|
NC6 |
Re:
News and media
|
|
Alv917
|
692 |
208K |
2 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
692
|
208K
|
2
|
|
ASX - By Stock
|
BCA |
Re:
Ann: Widespread Manganese Confirmed at Flanagan Bore Prospect
|
|
Alv917
|
7 |
2.9K |
5 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
7
|
2.9K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 Demonstrates World First Multiple Mechanisms of Action
|
|
Alv917
|
54 |
16K |
0 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
54
|
16K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
Alv917
|
370 |
105K |
4 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
370
|
105K
|
4
|
|
Economics
|
|
Re:
Charlie Monger on MMT
|
|
Alv917
|
60 |
13K |
6 |
03/05/21 |
03/05/21 |
Economics
|
60
|
13K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4C and Activity Report
|
|
Alv917
|
31 |
7.4K |
8 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
31
|
7.4K
|
8
|
|
Economics
|
Education |
Re:
Beginning trader
|
|
Alv917
|
2 |
1.3K |
1 |
24/04/21 |
24/04/21 |
Economics
|
2
|
1.3K
|
1
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Trading Halt
|
|
Alv917
|
22 |
8.8K |
3 |
14/04/21 |
14/04/21 |
ASX - By Stock
|
22
|
8.8K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Sinusitis Patient Update - Special Access Scheme
|
|
Alv917
|
140 |
31K |
8 |
08/04/21 |
08/04/21 |
ASX - By Stock
|
140
|
31K
|
8
|
|
ASX - By Stock
|
NIC |
Re:
ASX 200 Inclusion........
|
|
Alv917
|
82 |
35K |
5 |
25/02/21 |
25/02/21 |
ASX - By Stock
|
82
|
35K
|
5
|
|
ASX - By Stock
|
SRK |
Re:
Ann: Advances in the Development of Apurimac Iron Ore Project
|
|
Alv917
|
93 |
29K |
4 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
93
|
29K
|
4
|
|
Economics
|
|
Re:
Massive Inflation in Shipping Costs. And the Reasons (WolfStreet)
|
|
Alv917
|
5 |
1.5K |
0 |
17/02/21 |
17/02/21 |
Economics
|
5
|
1.5K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Further Encouraging COVID Results at Doherty
|
|
Alv917
|
100 |
22K |
1 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
100
|
22K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
RCE Price prediction At Asx close 31st March
|
|
Alv917
|
43 |
11K |
1 |
18/01/21 |
18/01/21 |
ASX - By Stock
|
43
|
11K
|
1
|
|
ASX - By Stock
|
NC6 |
Re:
General Discussion
|
|
Alv917
|
1.3K |
334K |
6 |
16/01/21 |
16/01/21 |
ASX - By Stock
|
1.3K
|
334K
|
6
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Nanollose and Grasim - Joint Patent - High Tenacity Lyocell
|
|
Alv917
|
129 |
31K |
0 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
129
|
31K
|
0
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Nanollose and Grasim - Joint Patent - High Tenacity Lyocell
|
|
Alv917
|
129 |
31K |
9 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
129
|
31K
|
9
|
|
ASX - By Stock
|
KAU |
Re:
predictions for relisting
|
|
Alv917
|
145 |
51K |
3 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
145
|
51K
|
3
|
|
ASX - By Stock
|
ANR |
Re:
Ann: Anatara Human Health Update
|
|
Alv917
|
12 |
4.7K |
3 |
27/12/20 |
27/12/20 |
ASX - By Stock
|
12
|
4.7K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Intranasal Animal Data against SARS-CoV-2 in Study
|
|
Alv917
|
48 |
13K |
1 |
24/12/20 |
24/12/20 |
ASX - By Stock
|
48
|
13K
|
1
|
|
Breaking News
|
|
Re:
Boy from Milan could be first known source of COVID-19
|
|
Alv917
|
128 |
16K |
8 |
13/12/20 |
13/12/20 |
Breaking News
|
128
|
16K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
COVID-19 Vaccines are not the answer.
|
|
Alv917
|
39 |
8.3K |
4 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
39
|
8.3K
|
4
|
|